FIELD: medicine, neurology, pharmacy. SUBSTANCE: invention relates to selective polypeptides and their using for neutralization of antibodies of human myelinic protein. Pharmaceutical composition has a peptide containing 8-25 amino acids as an active component. Peptide is able to neutralize antimyelinic basic protein. Method of treatment involves administration of peptide that contains 8-25 amino acids. Dose is 1.0-10.0 mg/kg body weight. The use of selective synthetic peptides for treatment of patients with cerebrospinal sclerosis will solve problems associated with a natural protein using. EFFECT: enhanced effectiveness of composition. 4 cl, 1 tbl, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE FRAGMENTS OF BASIC PROTEIN MYELIN, PHARMACEUTICAL COMPOSITIONS BASED ON THEREOF AND APPLICATION OF THESE COMPOSITIONS FOR TREATMENT OF CEREBROSPINAL SCLEROSIS | 1998 |
|
RU2198893C2 |
| PEPTIDE SPECIFICITY OF ANTIBODY TO MYELIN BASIC PROTEIN, PHARMACEUTICAL COMPOSITION CONTAINING THEREOF AND METHOD OF TREATMENT OF PATIENTS WITH CEREBROSPINAL SCLEROSIS | 1995 |
|
RU2157815C2 |
| VACCINE AND METHODS FOR DETECTION AND PREVENTION OF FILARIASIS | 2021 |
|
RU2832185C1 |
| GLYCAN-DEPENDENT IMMUNOTHERAPY MOLECULES | 2016 |
|
RU2754661C2 |
| DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
| ANTI-αvβ8 ANTIBODIES AND COMPOSITIONS AND THEIR USE | 2019 |
|
RU2812478C2 |
| COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN EXPRESSION | 2017 |
|
RU2795467C2 |
| CHIMERIC HUMAN MESOTHELIOGEN ANTIGEN RECEPTORS AND USE THEREOF | 2014 |
|
RU2714902C2 |
| NON-VIRAL IMMUNOTARGETING | 2020 |
|
RU2833379C2 |
| ONCOLYTIC HSV-VECTOR | 2014 |
|
RU2719190C2 |
